Sarepta Therapeutics Inc. (SRPT)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 105 |
Market Cap | 10.02B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 1.54 |
PE Ratio (ttm) | 68.12 |
Forward PE | n/a |
Analyst | Buy |
Ask | 106.77 |
Volume | 987,080 |
Avg. Volume (20D) | 868,438 |
Open | 102.60 |
Previous Close | 107.95 |
Day's Range | 101.15 - 106.10 |
52-Week Range | 101.15 - 173.25 |
Beta | undefined |
About SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of ...
Analyst Forecast
According to 21 analyst ratings, the average rating for SRPT stock is "Buy." The 12-month stock price forecast is $181, which is an increase of 72.55% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
Why Price Moved
News
![news image](https://images.financialmodelingprep.com/news/sareptas-elevidys-launch-remains-strong-with-solid-beat-says-20250113.jpg)
1 month ago · https://thefly.com
Sarepta's Elevidys launch remains strong with solid beat, says JPMorganSarepta + Arrowhead +0.18 (+0.97%)